Proceedings of the National Academy of Sciences of the United States of America (PNAS)2011ResearchDrug Delivery
Che-Ming J. Hu, Li Zhang, Santosh Aryal, Connie Cheung, Ronnie H. Fang, Liangfang Zhang
Long-circulating nanoparticles are needed for sustained systemic drug delivery, but PEGylation—the current stealth gold standard—can face anti-PEG immune responses. A top-down biomimetic approach using natural erythrocyte membranes could better mimic red blood cells (RBCs), nature’s long-circulating carriers, while…
Read the article →Journal of Controlled Release2011ResearchNon-viral Gene Delivery
Wong Sp, Argyros O, Howe Sj, Harbottle Rp
Nonviral vectors have rarely been tested in neonatal mice because of poor delivery efficiency, yet early gene therapy could prevent irreversible disease, requires lower vector doses due to small body size, and may avoid immune reactions before immune maturation. Viral vectors carry risks such as insertional…
Read the article →Polymers2011ReviewDrug Delivery
Hirenkumar K. Makadia And Steven J. Siegel
PLGA has become one of the most attractive biodegradable polymers for drug delivery and tissue engineering, but its degradation and drug-release behaviour depend on many interconnected variables—polymer composition, molecular weight, crystallinity, device geometry, fabrication method, and drug type. A consolidated…
Read the article →Proceedings of the National Academy of Sciences of the United States of America2010ResearchNon-viral Gene Delivery
Kevin T. Love, Kerry P. Mahon, Christopher G. Levins, Kathryn A. Whitehead, William Querbes, J. Robert Dorkin, June Qin, William Cantley, Liu Liang Qin, Timothy Racie, Maria Frank-Kamenetsky, Ka Ning Yip, Rene Alvarez, Dinah W. Y. Sah, Antonin De Fougerolles, Kevin Fitzgerald, Victor Koteliansky, Ak
Existing siRNA delivery systems required high doses (1 mg/kg) for hepatic gene silencing. A more potent, well-tolerated lipid-like delivery material was needed to enable low-dose RNAi therapeutics and multi-gene silencing in vivo. C12-200 enabled Factor VII silencing at doses below 0.01 mg/kg in mice, 100-fold more…
Read the article →Clinical Cancer Research2010ResearchNon-viral Gene Delivery
Han Hd, Mangala Ls, Lee Jw, Shahzad Mmk, Kim Hs, Shen D, Nam Ej, Mora Em, Stone Rl, Lu C, Lee Sj, Roh Jw, Nick Am, Lopez-Berestein G, Sood Ak
siRNA has therapeutic potential, but in vivo delivery is limited by rapid clearance, nuclease degradation, and nonspecific distribution. A tumour-targeted, biocompatible delivery system was needed to increase intratumoral siRNA accumulation, reduce off-target effects, and enable silencing of growth-promoting genes in…
Read the article →Nature Reviews Drug Discovery2010ReviewDrug Delivery
Robby A. Petros And Joseph M. Desimone
Engineered nanoparticles have shown promise for targeted drug delivery, but first-generation systems (liposomes and polymer–drug conjugates) have not overcome all biological barriers required for effective therapy. Key barriers include opsonisation and RES clearance, inefficient cargo encapsulation and triggered…
Read the article →Journal of Internal Medicine2010ReviewNon-viral Gene Delivery
Schroeder A, Levins Cg, Cortez C, Langer R, Anderson Dg
RNAi has strong therapeutic potential, but clinical translation of siRNA is limited by delivery. siRNA is large, negatively charged, susceptible to nuclease degradation, poorly taken up by cells, and must reach the cytoplasm to engage RISC. Safe and effective lipid-based delivery systems are needed to protect siRNA…
Read the article →Journal of Controlled Release2007ResearchNon-viral Gene Delivery
Ayumi Sato, Sung Won Choi, Miwa Hirai, Asako Yamayoshi, Rui Moriyama, Takeshi Yamano, Motoki Takagi, Arihiro Kano, Akira Shimamoto, Atsushi Maruyama
Systemic siRNA therapeutics are limited by poor cell membrane permeability, rapid nuclease degradation, and renal clearance. A carrier with long circulatory half-life is needed for effective RNAi and potential tumour targeting via the enhanced permeation and retention (EPR) effect. Existing hydrophilic…
Read the article →Bioorganic & Medicinal Chemistry (inferred from journal style; exact journal not stated in supplied excerpt)2007ResearchNon-viral Gene Delivery
Masato Yamagata, Takahito Kawano, Kouhei Shiba, Takeshi Mori, Yoshiki Katayama, Takuro Niidome
Gene carriers are often studied individually under different assay conditions, making direct structure–function comparisons difficult. The study compared dendritic poly(L-lysine) (KG6) and linear poly(L-lysine) (PLL) within the same experimental system to identify how carrier architecture affects DNA complex…
Read the article →Journal of Controlled Release2006ResearchNon-viral Gene Delivery
Katas H, Alpar Ho
siRNA has therapeutic potential but is limited by poor cellular uptake, rapid nuclease degradation, and poor blood stability. Chitosan was explored as a non-viral siRNA vector because of its low toxicity, biodegradability, biocompatibility, and cationic nature, but its use for siRNA delivery had not been…
Read the article →Journal of Controlled Release2006ResearchNon-viral Gene Delivery
DNA vaccines are limited by inefficient delivery to antigen-presenting cells (APCs) and lack of adjuvant effect, especially for weakly immunogenic self/tumor antigens. The study addresses this by using cationic PEI-functionalised PLGA microparticles to enhance APC activation and protective anti-tumour immunity…
Read the article →Journal of Controlled Release1998ResearchNon-viral Gene Delivery
Young Hun Choi, Feng Liu, Jin-Seok Kim, Young Kweon Choi, Jong Sang Park, Sung Wan Kim
Non-viral gene delivery systems such as poly-L-lysine (PLL) have low immunogenicity compared with viral vectors, but PLL suffers from poor biocompatibility, rapid degradation, and low transfection efficiency. PEGylation was explored to improve solubility, reduce cytotoxicity, and enhance cell permeability for gene…
Read the article →Molecular Membrane Biology1998ReviewNon-viral Gene Delivery
Hope Mj, Mui B, Ansell S, Ahkong Qf
Polymeric nucleic acid drugs—plasmid DNA, antisense oligonucleotides, and ribozymes—require protection from nucleases and efficient intracellular delivery to cytoplasm/nucleus. Viral vectors are efficient but immunogenic and safety-limited; non-viral cationic lipid systems are promising, but the mechanism of…
Read the article →Gene Therapy1997ResearchNon-viral Gene Delivery
S. Li And L. Huang
First-generation cationic liposome–DNA complexes showed insufficient in vivo gene transfer efficiency. A more virus-like, self-assembling non-viral vector was needed that could condense and protect plasmid DNA and produce efficient gene expression after systemic administration. LPD gave consistently higher in vivo…
Read the article →ResearchNon-viral Gene Delivery
Maria Buñuales, Nejat Düzgüneş, Sara Zalba, María J. Garrido & Conchita Tros De Ilarduya
Nonviral gene delivery vectors are safer than viral vectors but generally suffer from low and nonspecific transfection efficiency. EGFR is overexpressed on many tumour cells, making EGF-mediated targeting an attractive strategy to improve selectivity and gene delivery into cancer cells. EGF-lipoplexes were…
Read the article →ResearchNon-viral Gene Delivery
Qiu T, Gu P, Wusiman A, Ni H, Xu S, Zhang Y, Zhu T, He J, Liu Z, Hu Y, Liu J, Wang D
Conventional adjuvants such as aluminium and Freund’s adjuvants have limitations, including poor cell-mediated immunity and local toxicity. Ginseng stem-leaf saponins (GSLS) have immunomodulatory/adjuvant activity, but improved delivery systems are needed. Cubosomes are stable lipid cubic liquid crystalline…
Read the article →